Investing.com - Financial Markets Worldwide
🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Additional analysis of clinical data on Ritter's lead candidate RP-G28 show clear treatment effect with good safety profile; shares up 7%

Published 08/03/2017, 11:07 AM
© Reuters. Additional analysis of clinical data on Ritter's lead candidate RP-G28 show clear treatment effect with good safety profile; shares up 7%
QLGN
-
  • Thinly traded nano cap Ritter Pharmaceuticals (RTTR +7%) perks up on almost double normal on the heels of its announcement of results from an additional analysis of its Phase 2b/3 clinical trial evaluating lead candidate RP-G28 in people with lactose intolerance (LI).
  • The company says the additional data show a clear treatment effect with positive reductions in key symptoms of LI. Its safety profile was positive as well, with no treatment-related serious adverse events observed.
  • RP-G28, a highly purified galactooligosaccharide, is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. If approved, it will be the first drug cleared by the FDA for the indication.
  • Previously: Ritter Pharma 's lactose intolerance candidate RP-G28 shows positive effect in mid-stage study but only after excluding bad data; shares down 7% premarket (March 29)
  • Now read: Lexicon Likely Stuck For A Little While


Original article

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.